Gustavo Leone
Medical University of South Carolina, Hollings Cancer Center
12
0
4
N/A
0
7
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+16 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Andrew S. Kraft, MD
Medical University of South Carolina
Shared therapeutic areas:
Worked with same sponsors:
Uzair B. Chaudhary, MD
Medical University of South Carolina
Shared therapeutic areas:
Worked with same sponsors:
Bruce M Frankel, MD
Medical University of South Carolina, Dept. of Neurosciences, Division of Neurosurgery
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
John D. Hainsworth, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Worked with same sponsors:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Steven A. Rosenberg, MD, PhD
NCI - Surgery Branch
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
All 12 trials loaded